Surgery Partners, Inc. Annual Report: Comprehensive Investor Overview

Executive Summary

Surgery Partners, Inc. (Nasdaq: SGRY), a leading operator of surgical facilities, has released its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. This detailed report provides investors with crucial information on the company’s financial performance, strategic direction, risk factors, and governance. Below are the key highlights and potential price-sensitive insights from the filing.

Key Points from the Report

• Market Capitalization & Share Count: As of June 30, 2025, Surgery Partners’ market capitalization was approximately \$2.6 billion. As of February 23, 2026, there were 129,419,836 shares of common stock outstanding.
• Listing & Regulatory Status: The company’s common stock trades on the Nasdaq Global Select Market under the ticker SGRY. Surgery Partners is classified as a large accelerated filer and is not an emerging growth company or a shell company.
• Financial Reporting & Controls: Surgery Partners confirms compliance with all SEC filing requirements, including attestation of internal controls over financial reporting by a registered public accounting firm, under Section 404(b) of the Sarbanes-Oxley Act.
• Business Strategy: The company emphasizes growth via acquisitions and development of surgical facilities, especially ambulatory surgery centers (ASCs) and hospitals. Physician-owners play a significant role, and the company is actively monitoring regulatory risks related to investment structures.
• Risk Factors: The report details extensive risks, including reductions in government and private insurance payments, regulatory changes, compliance challenges, integration of IT systems, and pandemic threats. Of note, the company warns about its history of net losses and ongoing leverage, which could impact ability to raise capital and service debt.
• Privacy & Security Risks: The company highlights risks regarding data privacy, especially around health information, noting that any breaches could result in significant liability or reputational harm.
• Legal & Governance Risks: The largest shareholder has significant influence, potentially affecting major corporate actions. Anti-takeover provisions in the company’s charter and Delaware law may deter acquisition offers that could be favorable to shareholders.
• Regulatory & Reimbursement Risks: Changes in healthcare laws, payment methodologies, and government funding could materially impact Surgery Partners’ revenues. The report notes ongoing uncertainty around CMS reimbursement and the timing of payments from government programs.
• Acquisition Program Risks: The company’s acquisition strategy raises legal scrutiny, especially regarding physician-investor returns and compliance with federal safe harbor investment rules, which could expose the company to regulatory or legal actions.
• Forward-Looking Statements: The report contains numerous forward-looking statements regarding business strategy, financial performance, and industry outlook, but cautions that actual results may differ materially due to a broad range of known and unknown risks.

Potential Price-Sensitive Issues for Shareholders

• Regulatory and Reimbursement Uncertainty: A major theme in the report is the risk of reductions in payments from government healthcare programs (Medicare, Medicaid) and private insurers. Any adverse changes in reimbursement rates or methodologies could significantly impact revenues and profitability.
• Debt and Profitability Concerns: Surgery Partners has a history of net losses and carries significant debt. The company’s leverage limits financial flexibility, increases exposure to interest rate risk, and heightens vulnerability if cash flows falter. Investors should closely monitor future debt service capabilities and any signs of financial distress.
• Data Privacy and Security: The company’s exposure to privacy and cybersecurity risks is significant. Any material data breach could result in legal penalties, costs, and reputational damage, with possible effects on share value.
• Shareholder Influence and Governance: The largest shareholder’s substantial influence over corporate decisions and anti-takeover provisions may limit shareholder ability to influence the company or benefit from potential acquisition proposals.
• Acquisition Risks: The company’s aggressive acquisition program, particularly of ASCs and hospitals, faces legal and regulatory scrutiny. If regulators challenge the company’s investment structures or find violations, it could lead to financial penalties or forced changes to the business model.
• Pandemic/Epidemic Impact: The company acknowledges ongoing risk from pandemics or outbreaks of contagious diseases, which could disrupt operations and negatively affect financial results.
• Forward-Looking Uncertainty: Surgery Partners explicitly warns that forward-looking statements regarding strategy, financial results, or industry growth are subject to significant uncertainty and should not be relied upon for investment decisions without consideration of risk factors.

Additional Information for Investors

• SEC Filings and Disclosure: Surgery Partners provides all SEC filings and related investor documentation on its website. However, information found online is not incorporated by reference into SEC filings.
• Documents Incorporated by Reference: Portions of the company’s definitive proxy statement for the 2026 annual meeting of stockholders are incorporated into Part III of this report.

Conclusion

The Surgery Partners, Inc. 2025 Annual Report is rich in disclosures that have material implications for shareholders. Investors should pay close attention to the company’s regulatory and reimbursement risks, debt and profitability concerns, cybersecurity and privacy exposures, and governance structure. These issues may have direct effects on share value and future price movements. Any significant developments in these areas—such as changes in government payments, data breaches, legal rulings, or shifts in shareholder control—could be material and potentially move the share price.

Disclaimer: This article is a summary and analysis based on Surgery Partners, Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2025. It is intended for informational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Investors should conduct their own research and consult professional advisors before making investment decisions. Forward-looking statements are subject to substantial risks and uncertainties; actual results may differ materially.

View Surgery Partners, Inc. Historical chart here